Trial Profile

A Phase 1, Open-Label Study to Evaluate the Mutual Drug-Drug Interaction Potential Between Denifanstat and Resmetirom in Healthy Adult Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denifanstat (Primary) ; Resmetirom (Primary)
Indications Acne vulgaris; Astrocytoma; Breast cancer; Glioblastoma; Liver cancer; Liver disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Non-small cell lung cancer; Prostate cancer
Focus Pharmacokinetics
Sponsors Sagimet Biosciences

Most Recent Events

23 Jan 2026 Status changed from active, no longer recruiting to completed.
18 Dec 2025 Results presented in the Sagimet Biosciences media release.
17 Dec 2025 According to a Sagimet Biosciences media release, topline data from this trial are anticipated by the end of 2025 a

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com